Table 1.
Demographics and baseline characteristics of the 138 South Korean patients in this study with Crohn’s disease who received infliximab treatment n (%)
| Variables | Value |
| Male/female | 90/48 (65.2/34.8) |
| Median age at diagnosis (IQR) (yr) | 21 (19-27) |
| Median age at first infusion (IQR) (yr) | 27 (22-33) |
| Median duration of disease prior to first IFX (IQR) (mo) | 52 (13-91) |
| Indication for IFX treatment | |
| Luminal | 122 (88.4) |
| Perianal fistulizing | 16 (11.6) |
| Median follow-up of IFX treatment (IQR) (mo) | 47 (30-73) |
| Disease location at diagnosis | |
| L1 (ileum) | 19 (13.8) |
| L2 (colon) | 9 (6.5) |
| L3 (ileocolon) | 108 (78.3) |
| Not documented | 2 (1.4) |
| Disease behavior at diagnosis | |
| B1 (non-stricturing non-penetrating) | 115 (83.3) |
| B2 (stricturing) | 7 (5.1) |
| B3 (penetrating) | 16 (11.6) |
| Perianal fistula at diagnosis | |
| Active | 36 (26.1) |
| Previous | 26 (18.8) |
| Smoking status at diagnosis | |
| Current smoker | 26 (18.8) |
| Ex-smoker | 9 (6.6) |
| Never smoker | 103 (74.6) |
| Previous major abdominal surgery prior to first IFX | 44 (31.9) |
| Concomitant immunomodulators | |
| None | 73 (52.9) |
| Azathioprine/6-mercaptopurine | 64 (46.4) |
| Methotrexate | 1 (0.7) |
IQR: Interquartile range; IFX: Infliximab.